Samip Rajendra Master, MBBS

Samip Master practices at Texas Oncology PA in Houston, Texas.

Samip Master's NPI, 1477841682, was assigned on July 21, 2011. Samip Master graduated from LSU School of Medicine in Shreveport in 2014. Samip Master holds Louisiana license MD.207162.

Samip Master's primary practice is Texas Oncology PA, at 13215 Dotson Rd, Houston, TX 77070 in Harris County. The practice phone is (972) 997-8000.

Samip Master's primary practice is Texas Oncology PA in Houston, Texas. Samip Master is also affiliated with John Sealy Hospital. The medical group on file is Texas Oncology. Dmand AI also links Samip Master to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Samip Master practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Samip Master's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Samip Master is licensed in Louisiana.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, deep vein thrombosis (DVT), fluid and electrolyte imbalances, lung cancer, lymphoma and multiple myeloma among the conditions Samip Master treats.

CMS data shows 1,531 Medicare services from Samip Master across 10 procedure codes in 2024, for 275 Medicare patients. Medicare paid $117,543 for them.

CMS counts 275 Medicare patients who saw Samip Master in 2024. The largest group is 65 to 74, with 124 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 17% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Samip Master's median patient age at 67, with 54% women.

In 2024, Samip Master wrote 989 Medicare Part D claims for 134 patients. 85% of them were for generic drugs. CMS names the drug for 719 of them, across 22 drugs with 11 or more claims each, at $1,130,932 in total drug cost. In 2023, CMS named 849 claims across 31 drugs.

Samip Master accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Samip Master as offering telehealth.

Dmand AI links 28 papers to Samip Master, published from 2016 to 2025. 2018 was the busiest year, with 4. The most frequent topics are Antineoplastic Agents, Anemia, Sickle Cell and Leukemia, Myeloid, Acute. Samip Master has published most often in Anticancer Res. Samip Master's most frequent co-authors are Richard Preston Mansour, MD, Glenn Morris Mills, MD and Nebu V. Koshy, MD.

Dmand AI links Samip Master to 6 clinical trials, 4 of them phase 3 studies. 5 are still active or recruiting. Conditions studied include Lymphatic Metastasis, Melanoma and Multiple Myeloma. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 409 general payments to Samip Master from 55 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 51% of the total. Incyte Corporation paid the most, $3,823.

Samip Master graduated from LSU School of Medicine in Shreveport in 2014.

Samip Master is in network with 17 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.